keyword
MENU ▼
Read by QxMD icon Read
search

transplantation

keyword
https://www.readbyqxmd.com/read/28092916/differences-in-peripheral-blood-lymphocytes-between-brand-name-and-generic-tacrolimus-treated-in-stable-liver-transplant-recipients
#1
Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Dong Hyun Sinn, Gyu-Seong Choi, Jae Berm Park, Eun-Suk Kang, Suk-Koo Lee
No abstract text is available yet for this article.
January 9, 2017: Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre
https://www.readbyqxmd.com/read/28092909/immune-mediated-neuropathies-following-autologous-stem-cell-transplantation-for-multiple-myeloma-case-series-and-review-of-the-literature
#2
Ghulam Rehman Mohyuddin, Jacqueline Uy, Honhar Medhavi, Muhammad Salman Faisal, Muzaffar H Qazilbash
Neuropathy is a common finding in patients with multiple myeloma. Several different factors can cause neuropathy in these patients, such as the underlying disease itself, medications used for treatment, or immune-mediated processes. Immune-mediated neuropathies (IMN) consist of a heterogeneous spectrum of peripheral nerve disorders. Although IMN is associated with several hematological disorders, it remains a very rare complication of hematopoietic stem cell transplantation (HCT). We describe our experiences of 3 patients with multiple myeloma who experienced IMN following autologous HCT (auto-HCT)...
January 17, 2017: Acta Haematologica
https://www.readbyqxmd.com/read/28092899/b-cells-mimicking-blasts-after-an-allogeneic-stem-cell-transplantation
#3
Justine Coombs, Elsa Bera
No abstract text is available yet for this article.
August 11, 2016: Blood
https://www.readbyqxmd.com/read/28092881/unexpected-babesiosis-in-a-patient-with-worsening-anemia-after-allogeneic-hematopoietic-stem-cell-transplantation
#4
Najeebah A Bade, Jean A Yared
No abstract text is available yet for this article.
August 18, 2016: Blood
https://www.readbyqxmd.com/read/28092866/transmembrane-tumor-necrosis-factor-%C3%AE-promotes-the-recruitment-of-mdscs-to-tumor-tissue-by-upregulating-cxcr4-expression-via-tnfr2
#5
Hongping Ba, Baihua Li, Xiaoyan Li, Cheng Li, Anlin Feng, Yazhen Zhu, Jing Wang, Zhuoya Li, Bingjiao Yin
Myeloid-derived suppressor cells (MDSCs) accumulated in tumor sites promote immune evasion. We found that TNFR deficiency-induced rejection of transplanted tumor was accompanied with markedly decreased accumulation of MDSCs. However, the mechanism(s) behind this phenomenon is not completely understood. Here, we demonstrated that TNFR deficiency did not affect the amount of MDSCs in bone marrow (BM), but decreased accumulation of Gr-1(+)CD11b(+) MDSCs in the spleen and tumor tissues. The chemotaxis of Tnfr(-/-) MDSCs was prominently decreased in response to both tumor cell culture supernatants and tumor tissue homogenates from Tnfr(-/-) and wild-type mice, indicating an effect of TNFR signaling on chemokine receptor expression in MDSCs...
January 13, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28092777/controlling-the-3d-architecture-of-self-lifting-auto-generated-tissue-equivalents-slates-for-optimized-corneal-graft-composition-and-stability
#6
Ricardo M Gouveia, Elena González-Andrades, Juan C Cardona, Carmen González-Gallardo, Ana M Ionescu, Ingrid Garzon, Miguel Alaminos, Miguel González-Andrades, Che J Connon
Ideally, biomaterials designed to play specific physical and physiological roles in vivo should comprise components and microarchitectures analogous to those of the native tissues they intend to replace. For that, implantable biomaterials need to be carefully designed to have the correct structural and compositional properties, which consequently impart their bio-function. In this study, we showed that the control of such properties can be defined from the bottom-up, using smart surface templates to modulate the structure, composition, and bio-mechanics of human transplantable tissues...
December 23, 2016: Biomaterials
https://www.readbyqxmd.com/read/28092685/precision-oncology-for-acute-myeloid-leukemia-using-a-knowledge-bank-approach
#7
Moritz Gerstung, Elli Papaemmanuil, Inigo Martincorena, Lars Bullinger, Verena I Gaidzik, Peter Paschka, Michael Heuser, Felicitas Thol, Niccolo Bolli, Peter Ganly, Arnold Ganser, Ultan McDermott, Konstanze Döhner, Richard F Schlenk, Hartmut Döhner, Peter J Campbell
Underpinning the vision of precision medicine is the concept that causative mutations in a patient's cancer drive its biology and, by extension, its clinical features and treatment response. However, considerable between-patient heterogeneity in driver mutations complicates evidence-based personalization of cancer care. Here, by reanalyzing data from 1,540 patients with acute myeloid leukemia (AML), we explore how large knowledge banks of matched genomic-clinical data can support clinical decision-making. Inclusive, multistage statistical models accurately predicted likelihoods of remission, relapse and mortality, which were validated using data from independent patients in The Cancer Genome Atlas...
January 16, 2017: Nature Genetics
https://www.readbyqxmd.com/read/28092668/upregulation-of-ret-induces-perineurial-invasion-of-pancreatic-adenocarcinoma
#8
M Amit, S Na'ara, L Leider-Trejo, Y Binenbaum, N Kulish, E Fridman, A Shabtai-Orbach, R J Wong, Z Gil
Tumor spread along nerves, a phenomenon known as perineurial invasion, is common in various cancers including pancreatic ductal adenocarcinoma (PDAC). Neural invasion is associated with poor outcome, yet its mechanism remains unclear. Using the transgenic Pdx-1-Cre/KrasG12D /p53R172H (KPC) mouse model, we investigated the mechanism of neural invasion in PDAC. To detect tissue-specific factors that influence neural invasion by cancer cells, we characterized the perineurial microenvironment using a series of bone marrow transplantation (BMT) experiments in transgenic mice expressing single mutations in the Cx3cr1, GDNF and CCR2 genes...
January 16, 2017: Oncogene
https://www.readbyqxmd.com/read/28092486/use-of-polyclonal-monoclonal-antibody-therapies-in-transplantation
#9
Melissa Y Yeung, Steven Gabardi, Mohamed H Sayegh
For over thirty years, antibody (mAb)-based therapies have been a standard component of transplant immunosuppression, and yet much remains to be learned in order for us to truly harness their therapeutic capabilities. Current mAbs used in transplant directly target and destroy graft-destructive immune cells, interrupt cytokine and costimulation-dependent T and B cell activation, and prevent down-stream complement activation. Areas covered: This review summarizes our current approaches to using antibody-based therapies to prevent and treat allograft rejection...
January 16, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28092420/immune-modulation-by-the-hepatitis-c-virus-core-protein
#10
Cecilia Fernández-Ponce, Juan Pedro Muñoz-Miranda, Mikel M Arbulo-Echevarria, Rocío Litrán, Enrique Aguado, Francisco García-Cozar
Hepatitis C virus (HCV) infection is currently the most important cause of chronic viral hepatitis in the world and one of the most frequent indications for liver transplantation. HCV uses different strategies to evade the innate and adaptive immune response, and this evasion plays a key role in determining viral persistence. Several HCV viral proteins have been described as immune modulators. In this review, we will focus on the effect of HCV nucleocapsid core protein in the function of immune cells and its correlation with the findings observed in HCV chronically infected patients...
January 16, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28092357/risk-of-sinusoidal-obstruction-syndrome-in-allogeneic-stem-cell-transplantation-after-prior-gemtuzumab-ozogamicin-treatment-a-retrospective-study-from-the-acute-leukemia-working-party-of-the-ebmt
#11
G Battipaglia, M Labopin, A Candoni, R Fanin, J El Cheikh, D Blaise, M Michallet, A Ruggeri, N Contentin, J M Ribera, M Stadler, J Sierra, P A von dem Borne, A Bloor, G Socié, A Nagler, M Mohty
Gemtuzumab ozogamicin (GO) may increase the risk of sinusoidal obstruction syndrome (SOS) when used prior to allogeneic stem cell transplantation (HSCT). We assessed SOS incidence and outcomes after HSCT of 146 adults, with a median age of 50 years, previously receiving GO. SOS prophylaxis was used in 69 patients (heparin n=57, ursodeoxycholic acid n=8, defibrotide n=4). Cumulative incidence (CI) of SOS was 8% (n=11), with death in 3 patients. Median interval between last GO dose and HSCT was 130 days. Overall survival (OS) and SOS incidence did not differ for patients receiving GO ⩽3...
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092356/treatment-pathways-and-resource-use-associated-with-recurrent-hodgkin-lymphoma-after-autologous-stem-cell-transplantation
#12
J Radford, P McKay, R Malladi, R Johnson, A Bloor, F Percival, A Sureda, K S Peggs
No abstract text is available yet for this article.
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092355/highly-favorable-outcome-in-brca-mutated-metastatic-breast-cancer-patients-receiving-high-dose-chemotherapy-and-autologous-hematopoietic-stem-cell-transplantation
#13
L Boudin, A Gonçalves, R Sabatier, J Moretta, P Sfumato, P Asseeva, D Livon, F Bertucci, J-M Extra, C Tarpin, G Houvenaeghel, E Lambaudie, A Tallet, M Resbeut, H Sobol, E Charafe-Jauffret, B Calmels, C Lemarie, J-M Boher, P Viens, F Eisinger, C Chabannon
No abstract text is available yet for this article.
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092354/use-of-defibrotide-to-treat-transplant-associated-thrombotic-microangiopathy-a-retrospective-study-of-the-paediatric-diseases-and-inborn-errors-working-parties-of-the-european-society-of-blood-and-marrow-transplantation
#14
L Yeates, M A Slatter, S Bonanomi, F L W I Lim, S Y Ong, A Dalissier, W Barberi, A Shulz, M Duval, C Heilmann, A Willekens, W H Y Hwang, C Uderzo, P Bader, A R Gennery
No abstract text is available yet for this article.
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092353/non-myeloablative-conditioning-for-second-hematopoietic-cell-transplantation-for-graft-failure-in-patients-with-non-malignant-disorders-a-prospective-study-and-review-of-the-literature
#15
K Mallhi, P J Orchard, W P Miller, Q Cao, J Tolar, T C Lund
Allogeneic hematopoietic cell transplantation (HCT) effectively treats several non-malignant disorders such as selected lysosomal disorders, cerebral adrenoleukodystrophy and hemoglobinopathies. However, rates of graft failure (GF) in non-malignant populations exceed those of patients with malignant indications for HCT. Salvage conditioning regimens and outcomes for second HCT for GF vary immensely in the literature. We report 17 consecutive pediatric patients with non-malignant disorders who underwent a second allogenic HCT for GF using a non-myeloablative, low-dose busulfan-based regimen...
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092351/pulmonary-complications-post-hematopoietic-stem-cell-transplant-in-dyskeratosis-congenita-analysis-of-oxidative-stress-in-lung-fibroblasts
#16
C Sorge, L Pereboeva, E Westin, W T Harris, D R Kelly, F Goldman
No abstract text is available yet for this article.
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092350/long-term-renal-survival-in-patients-undergoing-t-cell-depleted-versus-conventional-hematopoietic-stem-cell-transplants
#17
I G Glezerman, S Devlin, M Maloy, M Bui, E A Jaimes, S A Giralt, A A Jakubowski
Calcineurin inhibitor (CNI)-sparing T-cell depleted (TCD) hematopoietic stem cell transplants (HSCTs) are presumed to be less nephrotoxic than conventional HSCTs. We evaluated incidence and risk factors for kidney failure and chronic kidney disease (CKD) in 231 TCD and 212 conventional HSCT recipients. Kidney failure required a median glomerular filtration rate (GFR) <60 ml/min/1.73 m(2) for ⩾100 days anytime after 180-days post-HSCT. Two-year cumulative incidence (CI) of kidney failure was 42% in the conventional versus 31% in the TCD group (P=0...
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092349/recipient-donor-hla-and-cmv-matching-in-recipients-of-t-cell-depleted-unrelated-donor-haematopoietic-cell-transplants
#18
B E Shaw, N P Mayor, R M Szydlo, W P Bultitude, C Anthias, K Kirkland, J Perry, A Clark, S Mackinnon, D I Marks, A Pagliuca, M N Potter, N H Russell, K Thomson, J A Madrigal, S G E Marsh
Improving haematopoietic cell transplantation outcomes by selection of an HLA-matched unrelated donor is best practice; however, donor selection by secondary characteristics is controversial. We studied 1271 recipients with haematological malignancies who underwent T-cell-depleted allografts and had complete data on HLA-matching status for six loci (HLA-A, -B, -C, -DRB1, -DQB1, -DPB1) and clinical outcome data. Five-year overall survival was 40.6%. HLA mismatching (at HLA-A, -B, -C, -DRB1, -DQB1) relative risk (RR) 1...
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092348/major-molecular-response-prior-to-allogeneic-hematopoietic-stem-cell-transplantation-predicts-better-outcome-in-adult-philadelphia-positive-acute-lymphoblastic-leukemia-in-first-remission
#19
W-Z Cai, J-N Cen, J Chen, F Chen, C-C Fu, Y Han, Z-M Jin, X Ma, M Miao, H-Y Qiu, X-W Tang, S-L Xue, A-N Sun, S-N Chen, D-P Wu
No abstract text is available yet for this article.
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092347/haploidentical-transplantation-with-post-infusion-cyclophosphamide-in-advanced-hodgkin-lymphoma
#20
L Castagna, S Bramanti, R Devillier, B Sarina, R Crocchiolo, S Furst, J E Cheikh, A Granata, C Faucher, S Harbi, L Morabito, J Mariotti, S Puvinathan, P J Weiller, C Chabannon, D Mokart, C Carlo-Stella, R Bouabdallah, A Santoro, D Blaise
We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD...
January 16, 2017: Bone Marrow Transplantation
keyword
keyword
3033
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"